Welcome to LookChem.com Sign In|Join Free
  • or
5,12-Naphthacenedione, 7-((4-O-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S,9S)is a complex chemical substance with a unique molecular structure. It comprises components such as 5,12-Naphthacenedione and 7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, which are indicative of the presence of multiple hydroxyl groups and an acetyl group. Additionally, 5,12-Naphthacenedione, 7-((4-O-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S,9S)- includes lyxo-hexopyranosyl derivatives, which are part of sugar or sugar derivative molecules. The "(7S,9S)-" in its name signifies the stereochemistry, highlighting the spatial arrangement of the atoms within the molecule. The properties and potential applications of this chemical are determined by its specific molecular structure and composition.

211100-13-9

Post Buying Request

211100-13-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

211100-13-9 Usage

Uses

Since the provided materials do not specify the uses of 5,12-Naphthacenedione, 7-((4-O-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-2,6-dideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S,9S)-, it is not possible to list its applications based on the given information. However, given its complex structure and the presence of sugar derivatives, it may have potential applications in various fields such as pharmaceuticals, materials science, or chemical research. Further investigation and experimentation would be required to determine its specific uses and benefits.

Check Digit Verification of cas no

The CAS Registry Mumber 211100-13-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,1,1,0 and 0 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 211100-13:
(8*2)+(7*1)+(6*1)+(5*1)+(4*0)+(3*0)+(2*1)+(1*3)=39
39 % 10 = 9
So 211100-13-9 is a valid CAS Registry Number.

211100-13-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (7S,9S)-7-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione

1.2 Other means of identification

Product number -
Other names UNII-XS499WOZ93

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:211100-13-9 SDS

211100-13-9Upstream product

211100-13-9Downstream Products

211100-13-9Relevant academic research and scientific papers

Impairment of myocardial contractility by anticancer anthracyclines: Role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue

Minotti, Giorgio,Parlani, Massimo,Salvatorelli, Emanuela,Menna, Pierantonio,Cipollone, Amalia,Animati, Fabio,Maggi, Carlo A.,Manzini, Stefano

, p. 1271 - 1278 (2007/10/03)

1 The anticancer anthracycline doxorubicin (DOX) causes cardiotoxicity. Enzymatic reduction of a side chain carbonyl group converts DOX to a secondary alcohol metabolite that has been implicated in cardiotoxicity. We therefore monitored negative inotropism, assessed as inhibition of post-rest contractions, in rat right ventricle strips exposed to DOX or to analogues forming fewer amounts of their alcohol metabolites (epirubicin, EPI, and the novel disaccharide anthracycline Men 10755). 2 Thirty μM EPI exhibited higher uptake than equimolar DOX, but formed comparable amounts of alcohol metabolite due to its resistance to carbonyl reduction. MEN 10755 exhibited also an impaired uptake, and consequently formed the lowest levels of alcohol metabolite. Accordingly, DOX and EPI inhibited post-rest contractions by ~40-50%, whereas MEN 10755 inhibited by ~6%. 3 One hundred μM EPI exhibited the same uptake as equimolar DOX, but formed ~50% less alcohol metabolite. One hundred μM MEN 10755 still exhibited the lowest uptake, forming ~60% less alcohol metabolite than EPI. Under these conditions DOX inhibited post-rest contractions by 88%. EPI and MEN 10755 were ~18% (P0.05) or ~80% (P0.001) less inhibitory than DOX, respectively. 4 The negative inotropism of 30-100 μM DOX, EPI, or MEN 10755 correlated with cellular levels of both alcohol metabolites (r=0.88, P0.0001) and carbonyl anthracyclines (r=0.79, P0.0001). Nonetheless, multiple comparisons showed that alcohol metabolites were ~20-40 times more effective than carbonyl anthracyclines in inhibiting contractility. The negative inotropism of MEN 10755 was therefore increased by chemical procedures, like side chain valeryl esterification, that facilitated its uptake and conversion to alcohol metabolite but not its retention in a carbonyl form. 5 These results demonstrate that secondary alcohol metabolites are important mediators of cardiotoxicity. A combination of reduced uptake and limited conversion to alcohol metabolite formation might therefore render MEN 10755 more cardiac tolerable than DOX and EPI.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 211100-13-9